As METTL3 depletion can decline oncogenes’ expression and reduce CRC proliferation (Shen et al., 2020), breast cancer (Li et al., 2020c), cervical cancer (Li et al., 2020c), and liver cancer (Wang et al., 2020c), METTL3 offers an alternative therapeutic target in colorectal cancer patients with high glucose levels (Shen et al., 2020). This evidence concerns the gene METTL3 and cervical cancer.